Doesn't it make it difficult for POH or partners to market TPM if you have Mylan offering a generic? Whether someone has successfully commercialized it is beside the point, they shouldn't be degrading the exclusivity offering of TPM which POH has the rights to.
Ann: Phosphagenics Arbitration Award Issued, page-217
-
- There are more pages in this discussion • 44 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add POH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.0¢ |
Change
0.000(0.00%) |
Mkt cap ! n/a | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
| POH (ASX) Chart |
Day chart unavailable
